Table 8 |
||
|
Application of IHC in primary diagnosis in confirmed cases (some patterns, partially overlapping cases) |
||
|
Year |
Confirmed cases |
IHC/markers in primary diagnostics |
|
|
||
|
1980-2002 |
49 (100%) |
|
|
19 (39%) |
No IHC performed |
|
|
4 (8%) |
No information available about eventual IHC use |
|
|
26 (53%) |
IHC, 1 till 18 markers |
|
|
No specific positive MM markers |
||
|
1988-1999 |
7 (14%) |
CEA, Vimentin and Pan-Cytokeratin |
|
Broad spectrum of non-specific markers |
||
|
1996, 1997 |
2 (4%) |
15/18 markers, 1st one incl. positive marker HBME-1, otherwise no specific positive MM markers |
|
Positive MM markers |
||
|
1998-2002 |
8 (16%) |
Calretinin, in all but one (1998) of cases combined with other markers, two cases with another positive marker - Thrombomodulin and HBME-1, respectively (n = 1-7) |
|
Negative MM markers |
||
|
1988-2002 |
17 (35%) |
CEA, in all but one (1990) of cases combined with other markers (n = 1-18) |
|
1996, 2002 |
2 (4%) |
CD15, combined with, amongst other markers, CEA and Ber-Ep4 (n = 15, 7) |
|
1996-2002 |
10 (20%) |
Ber-Ep4, combined with other markers (n = 4-15) |
|
|
||
|
Sandeck et al. Diagnostic Pathology 2010 5:47 doi:10.1186/1746-1596-5-47 |
||
